Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alvocidib - Tolero Pharmaceuticals

Drug Profile

Alvocidib - Tolero Pharmaceuticals

Alternative Names: Alvocidib hydrochloride; DSP-2033; Flavopiridol; HL-275; HMR 1275; IND 46211; L 868275; MDL-107826A; NSC 649890

Latest Information Update: 06 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer National Cancer Institute (USA); Tolero Pharmaceuticals
  • Class Antineoplastics; Benzopyrans; Flavonoids; Piperidines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; CDC2 protein kinase inhibitors; Cyclin dependent kinase 9 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Germ cell and embryonal neoplasms
  • Phase I/II Myelodysplastic syndromes
  • Preclinical Multiple myeloma
  • No development reported B-cell lymphoma; Chronic lymphocytic leukaemia
  • Discontinued HIV infections; Non-small cell lung cancer; Oesophageal cancer; Renal cancer; Reperfusion injury

Most Recent Events

  • 06 Dec 2018 Adverse events and efficacy data from the phase II ZELLA 201 trial in Acute myeloid leukaemia presented at the 60th Annual Meeting of the American Society of Hematology (ASH-2018)
  • 29 Aug 2018 Phase-I/II clinical trials in Myelodysplastic syndromes (Combination therapy, First-line therapy, Second-line therapy or greater) in USA (IV) (NCT03593915)
  • 20 Aug 2018 Tolero Pharmaceuticals enters into a research collaboration with AbbVie for Acute myeloid leukemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top